Currently, cancer is a primary cause of human death, which can be attributed to its high rates of morbidity and mortality in the United States and many other countries[@b1]. Large epidemiological and clinical investigations had indicated that a multitude of factors contribute to the initiation of tumourigenesis, such as environmental factors, hereditary factors and cancer-related lifestyle factors. Additionally, susceptibility genes, including EXO1[@b2], have been found to play a key role in the initiation of cancer.

The Exonuclease 1 (EXO1) gene, which belongs to the RAD2 nuclease family, encodes a member of the mismatch repair (MMR) system that plays a critical role in maintaining genomic stability[@b3]. EXO1 is located on chromosome 1q42--q43, includes one untranslated exon and 13 coding exons, and encodes an 846 amino acid protein. The products of the EXO1 gene function in DNA replication, repair, mutation avoidance and recombination, which are necessary processes for both male and female meiosis[@b4].

Recently, the associations between EXO1 genetic polymorphisms and susceptibility to various type of cancers had been widely investigated. An EXO1 polymorphism at codon 589 (rs1047840) is a non-synonymous single nucleotide polymorphism (SNP) that has been associated with susceptibility to lung cancer (LC)[@b5][@b6][@b7], glioma[@b8], breast cancer (BC)[@b9], and gastric cancer (GC)[@b10]. As such, it may be a novel useful marker for primary tumour prevention and anticancer interventions. However, other common low-penetrance susceptibility alleles may also exist, which lead to a moderate increase or reduction in cancer susceptibility. To date, only a few molecular epidemiological studies have investigated other EXO1 polymorphisms and cancer susceptibility in various populations, such as A-1419G (rs3754093), G670E (rs1776148), C498T (rs1635517), and L757P (rs9350). Additionally, no consensus had yet been obtained, which was partially a consequence of the heterogeneity within cancer subtypes, the diverse ethnicity of patient cohorts, and the small sample sizes. In the present meta-analysis, we had widely reviewed all eligible publications that were based on case-control data to derive a more precise and up-to-date estimation of associations between polymorphisms in EXO1 and cancer susceptibility.

Methods
=======

Literature search and eligibility
---------------------------------

We performed a comprehensive literature search using the PubMed, Web of Science, EMbase and Wangfang databases (last research update: September 29, 2015) in which we applied the following search terms: (EXO1 OR exonuclease 1) AND (polymorphism OR SNP OR variant OR mutation OR allele) AND (cancer OR tumour OR carcinoma OR neoplasm OR malignancy). We also manually retrieved reference lists from these enrolled publications, aiming to ensure that all eligible studies were included.

Inclusion and exclusion criteria
--------------------------------

The detailed inclusion criteria were as follows: 1) the study was a case-control study; 2) the study evaluated the association between EXO1 polymorphisms and cancer susceptibility; 3) the study comprised useful allele and genotype frequencies to estimate the crude ORs at 95% CIs. However, all meta-analyses, reviews, animal studies and case-only studies, as well as those duplicated previous publications, were definitely excluded. Studies deviated from Hardy Weinberg Equilibrium (HWE), studies that were not concerned with cancer susceptibility and abstracts with incomplete genetic data were also removed from this analysis. When a case group was investigated in more than one publication, the publication with the largest number of participants was selected.

Data extraction
---------------

The following information was extracted from each study by two independent investigators (Meng Zhang and Duran Zhao): name of the first author, year of publication, ethnicity, genotyping methods, source of controls, cancer type, total number of cases and controls, and HWE. Any discrepancies between the two investigators' selections were resolved by consensus. Regarding the sources of controls, all eligible case-control studies were defined as either population-based (PB) or hospital-based (HB).

Statistical analysis
--------------------

Susceptibility to cancer related to EXO1 polymorphisms was calculated directly from data provided in the eligible studies. Crude OR corresponding to 95% CI was applied to evaluate the strength of association between EXO1 polymorphisms and cancer susceptibility. Variants in EXO1 included rs1635498, rs1047840, rs851797, rs3754093, rs1776177, rs1776148, rs1635517, rs10802996 and rs9350. Each variable was analysed in allelic comparison, heterozygote comparison, homozygote comparison, dominant and recessive models. For example, the pooled ORs of EXO1 rs9350 polymorphisms were calculated by allelic comparison (T vs. C), heterozygote comparison (TC vs. CC), homozygote comparison (TT vs. CC), dominant (TT + TC vs. CC) and recessive models (TT vs. TC + CC). We used a χ^2^-based Q-test to evaluate between-study heterogeneity within the studies[@b11]. Heterogeneity was considered to be significant when the *P*-value was less than 0.1. If there was no significant heterogeneity, a fixed effect model (Der-Simonian Laird) was used to evaluate the point estimates and 95% CI; otherwise, a random effects model (Der-Simonian Laird) was used[@b12]. The *Z*-test was used to determine the significance of overall ORs. In addition, Bonferroni corrections were also performed to adjust the results[@b13]. If significant heterogeneity existed among the enrolled case-control studies, meta-regression was used to elaborate the source of heterogeneity with the Stata version 12.0 software. Moreover, one-way sensitivity analyses were carried out to evaluate the stability of the pooled ORs, in which each individual study was removed from the meta-analysis to detect the effect of each individual data set on the pooled ORs. Publication bias was evaluated using Begg's funnel plot and Egger's test based on Stata 12.0 software[@b14].

Linkage disequilibrium (LD) analysis across populations
-------------------------------------------------------

We extracted data from the 1000 genomes Project Phase III (<http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap3r2_B36/>) encompassing the polymorphisms in EXO1 evaluated in currently study[@b15]. Briefly, populations enrolled in the project including ASW (African ancestry in Southwest USA), CEU (Utah residents with Northern and Western European ancestry from the CEPH collection), CHB (Han Chinese in Beijing, China), CHD (Chinese in Metropolitan Denver, Colorado), GIH (Gujarati Indians in Houston, Texas), JPT (Japanese in Tokyo, Japan), LWK (Luhya in Webuye, Kenya), MEX (Mexican ancestry in Los Angeles, California), MKK (Maasai in Kinyawa, Kenya), TSI (Toscans in Italy) and YRI (Yoruba in Ibadan, Nigeria). Then, Haploview software was used to perform analysis and LD was evaluated by r^2^ statistics[@b16] in each of the above mentioned populations.

Results
=======

Study characteristics
---------------------

As shown in [Fig. 1](#f1){ref-type="fig"}, a total of 362 citations were retrieved from database searches. After reading the title or abstract, 41 studies concerning the associations of the nine EXO1 polymorphisms and cancer susceptibility were selected for further consideration. Then, 27 articles were removed because they were duplicated studies, lacked sufficient genotype information, or used ineligible samples. Finally, we collected 14 publications that encompassed 50 case-control studies, including 28,462 cases and 28,253 controls of the nine polymorphisms in EXO1 (rs1635498, rs1047840, rs851797, rs3754093, rs1776177, rs1776148, rs1635517, rs10802996 and rs9350) ([Table 1](#t1){ref-type="table"})[@b4][@b5][@b6][@b8][@b9][@b10][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24]. The quality of these enrolled case-control studies was evaluated using the Newcastle--Ottawa Scale (NOS) ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). Genotypic distribution of most of the studies was in agreement with HWE (*P* \> 0.05) in controls population except for 11 case-control studies[@b5][@b6][@b9][@b10][@b17][@b19][@b23], which were eventually excluded from the pooled analyses. In the end, a total of 11 publications, encompassing 39 case-control studies of the nine polymorphisms that involved 21,651 cases and 21,348 controls were finally enrolled.

For the rs1047840 polymorphism, 11 case-control studies with 6,289 cases and 6,333 controls met our inclusion criteria. Among these, four studies were of Caucasian individuals, five were of Asians and others were of mixed groups. For the rs9350 polymorphism, five case-control studies, which included 3,173 cases and 2,895 controls were enrolled. Among these, only one study was performed in a Caucasian cohort, while the others considered as Asian individuals. For rs1776177 polymorphism, three case-controls of Asians that encompassed 1,217 cases and 1,217 controls were enrolled. For the rs1776148 polymorphism, we ultimately enrolled two case-control studies of Caucasians that included 711 cases and 490 controls. For the rs10802996 polymorphism, two case-control studies of Asians that included 305 cases and 457 controls met our eligibility criteria. Moreover, for the rs851797, rs3754093, rs1635517 and rs1635498 polymorphisms, there were four case-control studies with 2,489 cases and 2,489 controls that were included in this present meta-analysis, and the ethnicity of these studies were of Asian populations.

Quantitative synthesis
----------------------

The results of rs1047840 and rs9350 polymorphisms and cancer risk were shown in [Table 2](#t2){ref-type="table"}, and the results of other polymorphisms were shown in [Supplementary Table 2](#S1){ref-type="supplementary-material"}. Overall, the pooled analysis indicated that the A allele (variant allele) of the rs1047840 polymorphism conferred a significantly increased overall susceptibility to cancer in an allelic model (A vs. G: OR = 4.082, 95% CI = 3.009--5.538, *P* = 0.000, [Fig. 2](#f2){ref-type="fig"}). Similarly, rs3754093 and rs1776177 polymorphisms were related to an increased susceptibility to cancer in an allelic model (rs3754093: G vs. A: OR = 2.976, 95% CI = 2.711--3.268, *P* = 0.000, [Fig. 3](#f3){ref-type="fig"}; rs1776177: G vs. A: OR = 3.234, 95% CI = 2.815--3.716, *P* = 0.000). Additionally, rs9350, rs10802996, rs1635498, rs1776148 and rs851797 polymorphisms were also conferred an increased overall susceptibility to cancer in an allelic model (rs9350: T vs. C: OR = 2.930, 95% CI = 2.124--4.042, *P* = 0.000; rs10802996: G vs. C: OR = 5.013, 95% CI: 3.717--6.762, *P* = 0.000; rs1635498: G vs. A: OR = 7.965, 95% CI: 6.924--9.163, *P* = 0.000; rs1776148: G vs. A: OR = 1.448, 95% CI: 1.209--1.734, *P* = 0.000; rs851797: T vs. C: OR = 1.841, 95% CI: 1.686--2.009, *P* = 0.000). However, no significant association was identified for rs1635517 polymorphism and overall cancer susceptibility.

Subgroup analyses
-----------------

Results of subgroup analyses were presented in [Table 2](#t2){ref-type="table"}. In an ethnicity subgroup analysis, a significantly increased susceptibility to cancer in Asian populations was identified in all the genetic models for rs1047840 polymorphism, while an increased susceptibility to cancer was identified for Caucasian populations only in an allelic model (A vs. G: OR = 2.709, 95% CI = 2.075--3.538, *P* = 0.000). When the subgroup analysis was conducted by source of control, an increased susceptibility to cancer was identified for P-B groups in an allelic model (A vs. G: OR = 4.357, 95% CI = 3.172--5.986, *P* = 0.000). In addition, we uncovered an increased susceptibility to lung cancer (LC) in an allelic model (A vs. G: OR = 4.510, 95% CI = 2.094--9.713, *P* = 0.000). In the stratification analysis by genotyping methods, an increased susceptibility to cancer was revealed for PCR-RFLP (A vs. G: OR = 5.327, 95% CI = 3.631--7.815, *P* = 0.000; AA + AG vs. GG: OR = 1.405, 95% CI = 1.144--1.726, *P* = 0.001) and SNP-Chip (A vs. G: OR = 2.488, 95% CI = 1.881--3.292, *P* = 0.000) groups, respectively.

For rs9350 polymorphism, when the stratification analysis was conducted based on genotyping method, we also identified a significant increased susceptibility to cancer in PCR-RFLP group in an allelic model (T vs. C: OR = 2.412, 95% CI = 2.201--2.643, *P* = 0.000) for Asian population.

Sensitivity analyses and publication bias
-----------------------------------------

Sensitivity analysis was performed by excluding each single case-control study in turn, and no individual study showed a significant influence on the pooled ORs. Sensitivity analysis of the rs1047840 polymorphism in an allelic comparison is presented in [Fig. 4](#f4){ref-type="fig"} ([Supplementary Table 3](#S1){ref-type="supplementary-material"}). Additionally, Begg's funnel plot was generated and Egger's test was performed to assess potential publication bias. The funnel plot of all polymorphisms was symmetrical. The funnel plot for the rs3754093 and rs1047840 polymorphisms in the allelic comparison was presented in [Figs 5](#f5){ref-type="fig"} and [6](#f6){ref-type="fig"}, respectively (rs3754093: G vs. A, Egger's funnel plot, *P* \> \|t\| = 0.349; rs1047840: G vs. A, Egger's funnel plot, P \> \|t\| = 0.337, [Supplementary Table 4](#S1){ref-type="supplementary-material"}).

LD analysis across populations
------------------------------

In order to better understand these results, LD analysis was performed to test for the existence of bins in the region comprising these eight polymorphisms (Meta-*P* value \< 0.05/45). However, only six of them can be matched from the database, including rs1635498, rs1047840, rs9350, rs1635517, rs1776148 and rs1776177 polymorphisms. LD plots for TSI population presented high LD value (r^2^ = 0.70) between rs1635517 and rs1776177 polymorphisms, for CHB, JPT, CHD and GIH populations presented moderate LD values (r^2^ ≥ 0.50), while for YRI, ASW and LWK populations presented a lower LD value (r^2^ \< 0.35) ([Fig. 6](#f6){ref-type="fig"} and [Supplementary Table 5](#S1){ref-type="supplementary-material"}). LD plots for CHB, JPT, CHD, GIH, LWK and MEX populations presented a lower LD value (r^2^ \< 0.35) between rs1776148 and rs9350 polymorphisms.

Discussion
==========

Multiple factors are involved in cancer formation and progression. Abundant evidence suggests that genetics play an important role in determining cancer susceptibility, and understanding associations between genetic polymorphisms and malignancies may provide personalized analysis and reveal the predictive value of certain carcinomas. An increasing number of research studies of tumourigenesis have highlighted EXO1 as a promising target.

The DNA repair system is known to be essential for maintaining genetic stability and offering protection from cancer initiation. EXO1 is an exclusive exonuclease gene that participates in the human MMR system. Genetic disorders in the MMR system result in the absence of DNA MMR function, resulting in an increased frequency of spontaneous mutations, which may give rise to the steady accumulation of oncogenes and tumour suppressors, which eventually contribute to tumourigenesis[@b20].

For rs1047840, one polymorphism in EXO1 is located on exon 12, and its variation leads to a change of the 589^th^ amino acid of the Exo1 protein from lysine to glutamic acid, which might affect EXO1 expression. For the rs1047840 polymorphism, it is located in an exonic splicing enhancer (ESE) region[@b6]. Previous studies suggest that the A allele (variant allele) of the rs1047840 polymorphism may influence EXO1 activity, which would mildly affect its normal function[@b5]; in addition, as people who harbour the A allele (s) become older, transformations caused by carcinogens may accumulate through an increased number of unremoved DNA adducts. Thus, for an individual who has a risk-imparting genetic variant, such as the A allele (variant allele) of the rs1047840 polymorphism, that variant will likely synergistically increase their cancer risk.

Owing to the importance of EXO1 polymorphisms, an increasing number of studies have explored the associations of EXO1 polymorphisms and cancer risk. Luo *et al*.[@b20] identified that the A allele of the EXO1 rs1047840 polymorphism was significantly related to an increased cervical cancer (CC) risk compared with the G allele (OR = 1.67, 95% CI: 1.13--2.45, *P* \< 0.05). Similarly, many other molecular epidemiological studies are consistent with this association of the EXO1 rs1047840 with BC, LC, oral cancer (OC) and GC[@b9][@b10][@b23][@b25]. However, Zienolddiny *et al*.[@b7] have shown no significant association of the rs1047840 polymorphism and non-small-cell gastric cancer (NSCGC) risk. Additionally, Song *et al*.[@b26] indicated that the rs3902093 polymorphism was related to reduced expression of EXO1 (*P*~discovery~ = 6.6 × 10−4, *P*~replication~ = 0.039, *P*~joint~ = 2.5 × 10−4; OR~joint~ = 0.80, 95% CI: 0.71--0.90), while carriers of the A allele had lower expression (*P* = 0.002).

As these findings are not conclusive, we conducted the present comprehensive meta-analysis to shed light on the role of EXO1 polymorphisms in tumourigenesis. Unlike the previous work conducted by Duan *et al*.[@b27], they only investigated one polymorphism in EXO1 and cancer risk and concluded that rs1047840 polymorphism A allele may be applied as a novel biomarker for tumour susceptibility. Recently, Chen *et al*.[@b28] also conducted a meta-analysis encompassing three polymorphisms in EXO1 and cancer risk, and they concluded that rs9350 polymorphism was a protective factor against cancer, while the rs1047840 polymorphism may be a risk factor. Besides, the rs1776148 polymorphism may have no influence on cancer risk. In our present work, which considered 21,651 cancer patients and 21,348 cancer free controls, we concluded that the A allele of rs1047840 polymorphism conferred a significantly increased susceptibility to overall cancer in an allelic model, a result consistent with previous meta-analysis[@b27][@b28]. Similarly, the rs3754093, rs1776177, rs9350, rs10802996, rs1635498, rs1776148 and rs851797 polymorphisms were also identified related to an increased overall susceptibility to cancer in an allelic model, respectively, while no significant association was revealed for rs1635517 polymorphism. For rs9350 and rs1776148, our conclusions were not consistent with Chen *et al*.'s[@b27] study, potentially because we excluded the studies that were deviated from HWE and our results were further adjusted by Bonferroni corrections[@b13]. In addition, when the stratification analyses were conducted by ethnicity and source of control, we identified a significantly increased susceptibility to Asian populations in all the genetic models of rs1047840 polymorphism, to Caucasians in an allelic model, and population-based (P-B) group in an allelic model. In addition, we uncovered an increased susceptibility to LC also in an allelic model. Moreover, we performed LD analyses to find the LD between the six polymorphisms, which showed that the rs1635517 and rs1776177 polymorphisms were in a high LD value (r^2^ = 0.70) for TSI population, and for CHB, JPT, CHD and GIH populations presented moderate LD values (r^2^ ≥ 0.50), while for YRI, ASW and LWK populations presented a lower LD value (r^2^ \< 0.35). However, our meta-analysis results seemed not to be in accordance with the LD analyses that rs1776177 polymorphism is a risk factor for cancer rather than rs1635517. Limited number of studies and sample size may account for this discrepancy, therefore, future studies are warranted to verify this finding.

There are some strengths and limitations in the present study. The most important strength is that we have conducted a comprehensive retrieval for all eligible studies and polymorphisms, and the sample size was markedly expanded, which helped to reveal some findings not suggested in the previous work. Secondly, studies deviated from HWE were excluded, ensuring the accuracy of the finally data. Simultaneously, several limitation should be discussed. Firstly, the phenotype of our study is a heterogeneous aggregation of a variety of cancer types, and only for rs1047840 polymorphism, a subgroup analysis based on cancer type was conducted, while for others, attributing to the limited number of studies for specific cancers, such as BC, CC and *etc.*, we are unable to validate the potential effects on these cancers homogeneous or not. In addition, as ten case-control studies were excluded from the pooled analysis, there retained only two case-control studies for rs10802996 and rs1776148 polymorphisms, respectively. On the basis of small samples, possibly leading to an underestimate of the true association. All these confusions should be further confirmed in a series of much larger studies. Secondly, the effects of EXO1 polymorphisms on cancer susceptibility might be affected by several factors, such as age, sex, smoking status and matching criteria. A lack of samples and data may cause inconsistency in results and lead to possible publication bias, which often affect the precision of overall results. Thirdly, tumours are polygenic diseases, and analyses of haplotype and gene-to-gene associations are also important because gene-to-gene and gene-to-environment interactions may modulate cancer susceptibility.

In conclusion, our meta-analysis suggests that the rs1047840, rs9350, rs10802996, rs1635498, rs1776148, rs1776177, rs3754093 and rs851797 polymorphisms in EXO1 may be risk factors for cancer. In the future, large-scale well-designed case-control studies are warranted to verify our findings.
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![Forest plots of the association between EXO1 rs1047840 polymorphism and cancer susceptibility (allelic comparison A vs. G).\
Each square indicate a study, and the area of squares is proportional to the weight of the study. The diamond represents the summary OR and 95% CI. CI = confidence interval, OR = odds ratio.](srep29270-f2){#f2}

![Forest plots of the association between EXO1 rs3754093 polymorphism and cancer susceptibility (allelic comparison G vs. A).\
Each square indicate a study, and the area of squares is proportional to the weight of the study. The diamond represents the summary OR and 95% CI. CI = confidence interval, OR = odds ratio.](srep29270-f3){#f3}
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![Begg's funnel plot for publication bias test under EXO1 rs3754093 (allelic comparison G vs. A).\
The x-axis is log (OR), and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.](srep29270-f5){#f5}

![Linkage disequilibrium analyses for EXO1 polymorphisms in populations from 1000 genomes Phase 3.\
The number of each cell represents r^2^ and white color cells shows no LD between polymorphisms. Population descriptors: ASW: African ancestry in Southwest USA, CEU: Utah residents with Northern and Western European ancestry from the CEPH collection, CHB: Han Chinese in Beijing, China, CHD: Chinese in Metropolitan Denver, Colorado, GIH: Gujarati Indians in Houston, Texas, JPT: Japanese in Tokyo, Japan, LWK: Luhya in Webuye, Kenya, MEX: Mexican ancestry in Los Angeles, California, MKK: Maasai in Kinyawa, Kenya, TSI: Toscans in Italy, YRI: Yoruba in Ibadan, Nigeria. The rs numbers are SNP IDs taken from National Center for Biotechnology Information (NCBI).](srep29270-f6){#f6}

###### Characteristics of the enrolled studies on EXO1 polymorphisms and cancer.

  SNP          First Author                 Year  Ethnicity   Genotyping Method   Source of control   Cancer Type     Case   Control                          
  ------------ --------------------------- ------ ----------- ------------------- ------------------- -------------- ------ --------- ----- ----- ----- ----- ---
  rs9350       Haghighi *et al*.            2010  Asian       PCR-RFLP            HB                  CRC              60      28       2    51    37    79    N
  rs9350       Bau *et al*.                 2009  Asian       PCR-RFLP            HB                  GC               62      78      39    56    84    39    Y
  rs9350       Wang *et al*.                2009  Asian       PCR-RFLP            HB                  BC              433      563     276   402   596   274   Y
  rs9350       Tsai *et al*.                2009  Asian       PCR-RFLP            HB                  OC              235      297     148   214   313   153   Y
  rs9350       Ibarrola-Villava *et al*.    2011  Caucasian   TaqMan              HB                  Melanoma        485      186     13    297   99    10    Y
  rs9350       Hsu *et al*.                 2009  Asian       PCR-RFLP            HB                  LC              124      156     78    112   167   79    Y
  rs851797     Bau *et al*.                 2009  Asian       PCR-RFLP            HB                  GC               38      87      54    36    90    53    Y
  rs851797     Wang *et al*.                2009  Asian       PCR-RFLP            HB                  BC              266      625     381   258   630   384   Y
  rs851797     Tsai *et al*.                2009  Asian       PCR-RFLP            HB                  OC              139      328     213   133   344   203   Y
  rs851797     Hsu *et al*.                 2009  Asian       PCR-RFLP            HB                  LC               76      173     109   72    179   107   Y
  rs3754093    Bau *et al*.                 2009  Asian       PCR-RFLP            HB                  GC               68      83      28    75    82    22    Y
  rs3754093    Wang *et al*.                2009  Asian       PCR-RFLP            HB                  BC              504      599     169   535   577   160   Y
  rs3754093    Tsai *et al*.                2009  Asian       PCR-RFLP            HB                  OC              261      311     108   283   315   82    Y
  rs3754093    Hsu *et al*.                 2009  Asian       PCR-RFLP            HB                  LC              135      167     56    149   164   45    Y
  rs1776177    Bau *et al*.                 2009  Asian       PCR-RFLP            HB                  GC               80      82      17    82    84    13    Y
  rs1776177    Wang *et al*.                2009  Asian       PCR-RFLP            HB                  BC              581      587     104   589   592   91    N
  rs1776177    Tsai *et al*.                2009  Asian       PCR-RFLP            HB                  OC              309      306     65    319   308   53    Y
  rs1776177    Hsu *et al*.                 2009  Asian       PCR-RFLP            HB                  LC              159      164     35    164   168   26    Y
  rs1776148    Bau *et al*.                 2009  Asian       PCR-RFLP            HB                  GC               9       39      131    8    36    135   N
  rs1776148    Wang *et al*.                2009  Asian       PCR-RFLP            HB                  BC               64      267     941   59    255   958   N
  rs1776148    Tsai *et al*.                2009  Asian       PCR-RFLP            HB                  OC               35      148     497   31    138   511   N
  rs1776148    Chang *et al*.               2008  Caucasian   SNP Chip            PB                  Glioblastoma     11      57      44    18    47    46    Y
  rs1776148    Ibarrola-Villava *et al*.    2011  Caucasian   PCR-RFLP            HB                  Melanoma         67      293     239   48    171   160   Y
  rs1776148    Hsu *et al*.                 2009  Asian       PCR-RFLP            HB                  LC               18      78      262   16    73    269   N
  rs1635517    Bau *et al*.                 2009  Asian       PCR-RFLP            HB                  GC               11      65      103    8    59    112   Y
  rs1635517    Wang *et al*.                2009  Asian       PCR-RFLP            HB                  BC               52      449     771   54    421   797   Y
  rs1635517    Tsai *et al*.                2009  Asian       PCR-RFLP            HB                  OC               39      241     400   28    218   434   Y
  rs1635517    Hsu *et al*.                 2009  Asian       PCR-RFLP            HB                  LC               22      130     206   15    118   225   Y
  rs1635498    Bau *et al*.                 2009  Asian       PCR-RFLP            HB                  GC              132      43       4    137   39     3    Y
  rs1635498    Wang *et al*.                2009  Asian       PCR-RFLP            HB                  BC              968      289     15    972   283   17    Y
  rs1635498    Tsai *et al*.                2009  Asian       PCR-RFLP            HB                  OC              508      161     11    522   148   10    Y
  rs1635498    Hsu *et al*.                 2009  Asian       PCR-RFLP            HB                  LC              265      85       8    274   79     5    Y
  rs10802996   Luo *et al*.                 2012  Asian       PCR-RFLP            HB                  CC               77      39      10    172   89    17    Y
  rs10802996   Bau *et al*.                 2009  Asian       PCR-RFLP            HB                  GC              100      59      20    102   61    16    Y
  rs10802996   Wang *et al*.                2009  Asian       PCR-RFLP            HB                  BC              735      408     129   728   426   118   N
  rs10802996   Tsai *et al*.                2009  Asian       PCR-RFLP            HB                  OC              380      235     65    383   235   62    N
  rs10802996   Hsu *et al*.                 2009  Asian       PCR-RFLP            HB                  LC              199      119     40    203   122   33    N
  rs1047840    Kabzińśki *et al*.           2014  Caucasian   TaqMan              PB                  CRC              22      95      33    49    62    39    N
  rs1047840    Nogueira *et al*.            2014  Mix         TaqMan              HB                  HNSCC           179      209     62    175   211   64    Y
  rs1047840    Tang *et al*.                2014  Mix         SNP Chip            HB                  PC              827      910     296   815   993   304   Y
  rs1047840    Luo *et al*.                 2012  Asian       PCR-RFLP            HB                  CC               73      48       5    196   77     5    Y
  rs1047840    Tsai *et al*.                2009  Asian       PCR-RFLP            HB                  OC              391      244     45    482   183   15    Y
  rs1047840    Wang *et al*.                2009  Asian       PCR-RFLP            HB                  BC              794      421     57    898   341   33    Y
  rs1047840    Bau *et al*.                 2009  Asian       PCR-RFLP            HB                  GC              103      64      12    125   49     5    Y
  rs1047840    Jin *et al*.                 2008  Asian       SNP Chip            PB                  LC              304      172     24    355   138   24    N
  rs1047840    Zienolddiny *et al*.         2005  Caucasian   Beckman             HB                  LC              115      106     35    116   145   30    Y
  rs1047840    Hsu *et al*.                 2009  Asian       PCR-RFLP            HB                  LC              214      125     19    251   97    10    Y
  rs1047840    Bayram *et al*.              2011  Caucasian   PCR-RFLP            HB                  HCC              95      94      35    99    108   17    Y
  rs1047840    Chang *et al*.               2008  Caucasian   SNP Chip            PB                  Glioblastoma     55      42      15    29    59    22    Y
  rs1047840    Ibarrola-Villava *et al*.    2011  Caucasian   PCR-RFLP            HB                  Melanoma        234      282     83    136   175   68    Y

CRC: Colorectal cancer; GC: gastric cancer; BC: Breast cancer; OC: Oral cancer; LC: Lung cancer; CC: Cervical cancer; HNSCC: Head and eck squamous cell carcinoma; PC: Pancreatic cancer; HCC: Hepatic cellular cancer; H-B: Hospital based; P-B: Population based; HWE: Hardy Weinberg Equilibrium.

###### Results of meta-analysis for polymorphisms in and cancer susceptibility.

  Polymorphisms   Comparison       Subgroup         N    *P*~H~    *P*~Z~            Random                 Fixed
  --------------- ---------------- --------------- ---- -------- ----------- ---------------------- ----------------------
  rs1047840       B VS. A          Overall          11   0.000    **0.000**   4.082 (3.009--5.538)   3.571 (3.350--3.807)
                  B VS. A          Asian            5    0.963    **0.000**   6.861 (6.127--7.682)   6.864 (6.130--7.687)
                  B VS. A          Caucasian        4    0.028    **0.000**   2.709 (2.075--3.538)   2.654 (2.301--3.060)
                  B VS. A          Mix              2    0.838    **0.000**   2.692 (2.452--2.955)   2.692 (2.452--2.955)
                  B VS. A          PCR-RFLP         7    0.000    **0.000**   5.327 (3.631--7.815)   5.057 (4.600--5.560)
                  B VS. A          SNP-Chip         2    0.175    **0.000**   2.488 (1.881--3.292)   2.662 (2.407--2.944)
                  B VS. A          Other methods    2    0.434    **0.000**   2.778 (2.330--3.313)   2.778 (2.330--3.312)
                  B VS. A          HB               10   0.000    **0.000**   4.357 (3.172--5.986)   3.615 (3.389--3.857)
                  B VS. A          LC               2    0.000    **0.000**   4.510 (2.094--9.713)   4.382 (3.546--5.416)
                  B VS. A          Other tumors     9    0.000    **0.000**   3.993 (2.824--5.647)   3.499 (3.272--3.742)
                  BA VS. AA        Overall          11   0.000      0.396     1.091 (0.892--1.336)   1.100 (1.019--1.187)
                  BA VS. AA        Asian            5    0.819    **0.000**   1.503 (1.335--1.691)   1.502 (1.335--1.691)
                  BA VS. AA        Caucasian        4    0.048      0.071     0.748 (0.545--1.026)   0.799 (0.665--0.961)
                  BA VS. AA        Mix              2    0.661      0.143     0.914 (0.811--1.031)   0.914 (0.811--1.031)
                  BA VS. AA        PCR-RFLP         7    0.020      0.002     1.339 (1.117--1.605)   1.358 (1.223--1.508)
                  BA VS. AA        SNP-Chip         2    0.005      0.261     0.612 (0.261--1.44)    0.866 (0.761--0.985)
                  BA VS. AA        Other methods    2    0.243      0.229     0.865 (0.665--1.125)   0.873 (0.699--1.090)
                  BA VS. AA        HB               10   0.000      0.112     1.165 (0.965--1.406)   1.121 (1.038--1.210)
                  BA VS. AA        LC               2    0.004      0.870     1.061 (0.525--2.143)   1.098 (0.866--1.393)
                  BA VS. AA        Other tumors     9    0.000      0.418     1.097 (0.877--1.372)   1.100 (1.015--1.192)
                  BA + BB VS. AA   Overall          11   0.000      0.256     1.132 (0.914--1.401)   1.129 (1.051--1.214)
                  BA + BB VS. AA   Asian            5    0.611    **0.000**   1.585 (1.414--1.776)   1.584 (1.414--1.775)
                  BA + BB VS. AA   Caucasian        4    0.020      0.131     0.774 (0.555--1.080)   0.824 (0.693--0.980)
                  BA + BB VS. AA   Mix              2    0.739      0.173     0.925 (0.826--1.035)   0.925 (0.826--1.035)
                  BA + BB VS. AA   PCR-RFLP         7    0.002    **0.001**   1.405 (1.144--1.726)   1.413 (1.278--1.562)
                  BA + BB VS. AA   SNP-Chip         2    0.002      0.270     0.609 (0.252--1.471)   0.877 (0.777--0.990)
                  BA + BB VS. AA   Other methods    2    0.441      0.340     0.903 (0.732--1.114)   0.903 (0.732--1.114)
                  BA + BB VS. AA   HB               10   0.000      0.052     1.219 (0.998--1.489)   1.152 (1.071--1.239)
                  BA + BB VS. AA   LC               2    0.005      0.699     1.137 (0.593--2.179)   1.169 (0.931--1.467)
                  BA + BB VS. AA   Other tumors     9    0.000      0.322     1.129 (0.888--1.437)   1.125 (1.042--1.214)
                  BB VS. AA        Overall          11   0.000      0.068     1.379 (0.977--1.948)   1.139 (1.003--1.293)
                  BB VS. AA        Asian            5    0.556    **0.000**   2.456 (1.818--3.317)   2.480 (1.839--3.344)
                  BB VS. AA        Caucasian        4    0.002      0.778     0.914 (0.488--1.711)   0.903 (0.695--1.173)
                  BB VS. AA        Mix              2    0.954      0.615     0.957 (0.808--1.135)   0.957 (0.808--1.135)
                  BB VS. AA        PCR-RFLP         7    0.000      0.011     2.004 (1.176--3.414)   1.625 (1.309--2.018)
                  BB VS. AA        SNP-Chip         2    0.019      0.350     0.636 (0.246--1.643)   0.910 (0.759--1.092)
                  BB VS. AA        Other methods    2    0.535      0.894     1.022 (0.737--1.418)   1.022 (0.737--1.418)
                  BB VS. AA        HB               10   0.000      0.014     1.529 (1.089--2.149)   1.175 (1.033--1.337)
                  BB VS. AA        LC               2    0.193      0.097     1.519 (0.823--2.804)   1.462 (0.934--2.288)
                  BB VS. AA        Other tumors     9    0.000      0.140     1.350 (0.907--2.011)   1.114 (0.976--1.272)
                  BB VS. BA + AA   Overall          11   0.000      0.030     1.369 (1.031--1.819)   1.151 (1.022--1.298)
                  BB VS. BA + AA   Asian            5    0.642      0.000     2.155 (1.600--2.904)   2.177 (1.618--2.929)
                  BB VS. BA + AA   Caucasian        4    0.005      0.771     1.085 (0.626--1.881)   1.007 (0.789--1.284)
                  BB VS. BA + AA   Mix              2    0.812      0.954     1.005 (0.858--1.176)   1.005 (0.858--1.176)
                  BB VS. BA + AA   PCR-RFLP         7    0.000      0.015     1.832 (1.123--2.987)   1.489 (1.209--1.835)
                  BB VS. BA + AA   SNP-Chip         2    0.189      0.867     0.900 (0.594--1.361)   0.986 (0.833--1.166)
                  BB VS. BA + AA   Other methods    2    0.275      0.578     1.100 (0.784--1.542)   1.090 (0.804--1.478)
                  BB VS. BA + AA   HB               10   0.000      0.011     1.460 (1.089--1.959)   1.173 (1.039--1.324)
                  BB VS. BA + AA   LC               2    0.467      0.050     1.533 (0.995--2.362)   1.539 (1.000--2.367)
                  BB VS. BA + AA   Other tumors     9    0.000      0.081     1.336 (0.965--1.852)   1.124 (0.992--1.273)
  rs9350          B VS. A          Overall          5    0.000      0.000     2.930 (2.124--4.042)   2.656 (2.435--2.896)
                  B VS. A          Asian            4    0.999      0.000     2.412 (2.201--2.643)   2.412 (2.201--2.643)
                  B VS. A          PCR-RFLP         4    0.999      0.000     2.412 (2.201--2.643)   2.412 (2.201--2.643)
                  BA VS. AA        Overall          5    0.513      0.105     0.908 (0.809--1.020)   0.909 (0.809--1.020)
                  BA VS. AA        Asian            4    0.996      0.027     0.866 (0.762--0.983)   0.866 (0.762--0.983)
                  BA VS. AA        PCR-RFLP         4    0.996      0.027     0.866 (0.762--0.983)   0.866 (0.762--0.983)
                  BA + BB VS. AA   Overall          5    0.637      0.105     0.914 (0.820--1.019)   0.914 (0.820--1.019)
                  BA + BB VS. AA   Asian            4    0.993      0.035     0.880 (0.782--0.991)   0.880 (0.782--0.991)
                  BA + BB VS. AA   PCR-RFLP         4    0.993      0.035     0.880 (0.782--0.991)   0.880 (0.782--0.991)
                  BB VS. AA        Overall          5    0.995      0.207     0.907 (0.780--1.055)   0.907 (0.780--1.055)
                  BB VS. AA        Asian            4    0.989      0.236     0.911 (0.782--1.062)   0.911 (0.782--1.062)
                  BB VS. AA        PCR-RFLP         4    0.989      0.236     0.911 (0.782--1.062)   0.911 (0.782--1.062)
                  BB VS. BA + AA   Overall          5    0.978      0.816     0.984 (0.862--1.124)   0.984 (0.862--1.124)
                  BB VS. BA + AA   Asian            4    0.991      0.891     0.991 (0.866--1.133)   0.991 (0.866--1.133)
                  BB VS. BA + AA   PCR-RFLP         4    0.991      0.891     0.991 (0.866--1.133)   0.991 (0.866--1.133)

*P*~H~: *P* value of Q test for heterogeneity test; *P*~Z~: means statistically significant (P \< 0.05); *P* (Adjust): Multiple testing *P* value according to Bonferroni Correction; LC: Lung cancer; H-B: Hospital based; P-B: Population based; HWE: Hardy Weinberg Equilibrium; *P* value less than 0.05/(9~polymorphisms~\*5~models~) was considered as statistically significant, which was marked with bold font in the table). Note: Heterogeneity was considered to be significant when the *P*-value was less than 0.1. If there was no significant heterogeneity, a fixed effect model (Der-Simonian Laird) was used to evaluate the point estimates and 95% CI; otherwise, a random effects model (Der-Simonian Laird) was used. And the *P*z was calculated based on the actual model adopted.
